Here's What's Pushing Up Esperion Therapeutics Inc. Today

Here's What's Pushing Up Esperion Therapeutics Inc. Today

Shares of Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical-stage biotech focused on reducing cholesterol, popped up again this morning in response to top-line clinical trial results for its lead candidate. The stock was up 19.8% as of 11:10 a.m. EDT during Tuesday's session.

Esperion's wagons are tightly circled around bempedoic acid, its only drug in clinical trials at the moment. This morning, the company announced results from a 60-patient mid-stage study that met its main goal with flying colors. 

Image source: Getty Images.

Continue reading

Source: Fool.com